Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Platinum vs non‐platinum therapy

Time to progression · women with metastatic triple‐negative breast cancer (mTNBC)

It is very uncertain whether platinum changes progression‐free survival/time to progression (PFS/TTP) compared with non‐platinum regimens (very low certainty).

1 finding from 1 review

Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
HR 0.77 [0.68, 0.88]
8 studies · 1077 participants
Very low

Intervention not reported

Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)

The intervention may leads to lower progression‐free survival/time to progression (randomised… (low certainty).

1 finding from 1 review

Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
HR 0.59 [0.49, 0.72]
3 studies · 391 participants
Low

Intervention not reported

Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)

The intervention showed no clear difference in progression‐free survival/time to progression (randomised… (moderate certainty).

1 finding from 1 review

Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
HR 0.92 [0.84, 1.01]
13 studies · 1745 participants
Moderate